title: Niosome as a drug carrier for topical delivery of N-acetyl glucosamine.
abstract: Niosomes are non-ionic surfactant vesicles that have potential applications in the delivery of hydrophilic and hydrophobic drugs. The topical form of N-acetyl glucosamine (NAG) recently has been considered in the treatment of hyperpigmentation disorders due to its inhibitory effect on thyrosinase enzymes in melanocytes. To improve NAG penetration into the skin we formulated the drug in niosomes and investigated its flux across excised rat skin using Franz diffusion cells. The drug assay was performed by a novel and specific high performance liquid chromatography method. Niosomal vesicles were further characterized by optical and scanning electron microscopy and particle size analysis. Niosomes prepared with Span 40 produced a drug encapsulation of about 50%. The vesicle size was markedly dependent on the composition of the niosome formulations and was in range of 500-4500 nm (Span 80 < Span 60 < Span 40 niosomes). Span 40-niosomes provided a higher NAG flux across the skin than Span 60- and Span 80-nisomes. All formulations significantly improved the extent of drug assessed to be localized in the skin (P< 0.05), as compared to NAG hydroalcoholic (HA) solution. Our study demonstrated the potential of niosomes for improved NAG localization in the skin, as needed in hyperpigmentation disorders.
authors: Department of Pharmaceutics and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R.Iran.
authors: M A
authors: MA
authors: Shatalebi
authors: S A
authors: SA
authors: Mostafavi
authors: A
authors: A
authors: Moghaddas
references: J Invest Dermatol. 1989 Jul;93(1):100-7
references: 2501395
references: Pharm Res. 1991 Sep;8(9):1079-86
references: 1788152
references: J Invest Dermatol. 1985 Aug;85(2):165-8
references: 3926905
references: Pharm Res. 1999 Jun;16(6):841-6
references: 10397603
references: Int J Pharm. 2006 Oct 12;323(1-2):1-10
references: 16837150
references: J Control Release. 1999 Aug 27;61(1-2):9-19
references: 10469899
references: Int J Pharm. 2001 Mar 14;215(1-2):91-9
references: 11250095
references: Skin Pharmacol Physiol. 2004 Mar-Apr;17(2):77-83
references: 14976384
references: Emerg Nurse. 2014 Sep;22(5):12
references: 25185909
references: Int J Dermatol. 1994 Feb;33(2):119-22
references: 8157393
references: J Control Release. 1998 Jul 31;54(2):149-65
references: 9724902
references: Cancer Res. 1982 May;42(5):1994-2002
references: 6802485
references: J Invest Dermatol. 1984 Sep;83(3):196-201
references: 6432920
references: J Invest Dermatol. 1983 Aug;81(2):106-14
references: 6409969
references: J Invest Dermatol. 1986 Sep;87(3):319-25
references: 3734483
references: Drug Dev Ind Pharm. 2005 Jan;31(1):91-7
references: 15704860
references: J Invest Dermatol. 1990 Jul;95(1):39-49
references: 2114451
references: J Pharm Sci. 1997 May;86(5):573-8
references: 9145381
references: Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):207-13
references: 15452406